CSPC Pharmaceutical Group Ltd CHJTF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Chinese Biopharma Stocks Rally as Investors Favor Healthcare Over AI
-
AstraZeneca Strikes Multibillion-Dollar Obesity Deal With China's CSPC Pharmaceuticals — 2nd Update
-
AstraZeneca Strikes Obesity Multibillion-Dollar Deal With China's CSPC Pharmaceuticals — Update
-
CSPC Pharma Shares Drop on Possible Profit-Taking After AstraZeneca Deal
-
AstraZeneca Strikes Multibillion-Dollar Obesity Deal With China's CSPC
-
Chinese Pharma Group CSPC's Unit Proceeds With Hong Kong Offering
Trading Information
- Previous Close Price
- $1.11
- Day Range
- $1.11–1.26
- 52-Week Range
- $0.94–1.39
- Bid/Ask
- $0.62 / $1.62
- Shares Outstanding
- 11.41B
- Market Cap
- $12.66B
- Volume/Avg
- 345,558 / 89,029
Key Statistics
- Price/Earnings (Normalized)
- 11.85
- Price/Sales
- 2.83
- Dividend Yield (Trailing)
- 3.79%
- Dividend Yield (Forward)
- 4.14%
- Dividend Payment Schedule
- Jul, Nov
- Total Yield
- 3.79%
Company Profile
CSPC Pharmaceutical Group LTD is engaged in the manufacture and sale of pharmaceutical products. The group's segments include: Finished drugs, consisting research and development, manufacture and sale of pharmaceutical products and license fee income; Bulk products, that manufacture and sale of vitamin C, and antibiotic products in bulk powder form; and Functional food and others, that manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. It derives maximum revenue from Finished Products segments. Geographically, the company operates in Chinese Mainland, which Chinese Mainland generates maximum revenue; Other Asian regions; Europe; North America; and Others.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Core
- Total Number of Employees
- 18,626
- Website
- https://www.cspc.com.hk
Valuation
|
Metric
|
CHJTF
|
|---|---|
Price/Earnings (Normalized) | 11.85 |
Price/Book Value | 2.29 |
Price/Sales | 2.83 |
Price/Cash Flow | 6.56 |
Price/Earnings
CHJTF
Financial Strength
|
Metric
|
CHJTF
|
|---|---|
Quick Ratio | 1.90 |
Current Ratio | 2.14 |
Interest Coverage | 299.30 |
Quick Ratio
CHJTF
Profitability
|
Metric
|
CHJTF
|
|---|---|
Return on Assets (Normalized) | 14.89% |
Return on Equity (Normalized) | 21.30% |
Return on Invested Capital (Normalized) | 19.64% |
Return on Assets
CHJTF
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|$$&FWrG | LOCK|$F | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|cvWd!Q | LOCK|by | $635B | |||
| AbbVie Inc
ABBV
| LOCK|LwV@@D | LOCK|N$$ | $505B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|@^<?xgl | LOCK|>F! | $381B | |||
| Merck & Co Inc
MRK
| LOCK|Xpf&@?& | LOCK|<?@ | $358B | |||
| Novartis AG ADR
NVS
| LOCK|$wfFGBdG | LOCK|s# | $297B | |||
| AstraZeneca PLC
AZN
| LOCK|#BvP>##D | LOCK|$V | $267B | |||
| Amgen Inc
AMGN
| LOCK|!v!^Zc< | LOCK|yY | $237B | |||
| Gilead Sciences Inc
GILD
| LOCK|Z&%J<? | LOCK|gd% | $193B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|J%!B<%P | LOCK|Jrx | $172B |
United States